-
2023-504830-23-00
5
2020-12-16
B-cell Lymphoma
-
2024-514468-26-00
9
2020-12-04
Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), O
-
2024-515953-52-00
5
2020-07-24
Post-Essential Thrombocythaemia Myelofibrosis
-
2023-509089-39-00
5
2020-07-01
Non-Muscle Invasive Bladder Cancer
-
2023-508292-37-00
5
2020-03-06
Cardiovascular Disease
-
2024-511747-25-00
4
2019-12-23
B-cell non-Hodgkin lymphoma (NHL)
-
2023-507886-25-00
4
2019-09-27
Previously untreated and symptomatic patients with histologically prov
-
2024-511641-18-00
4
2019-08-01
Diffuse Large B-cell Lymphoma ABC
-
2024-514823-41-00
4
2019-04-29
Chronic Lymphocytic Leukemia (CLL)
-
2024-514686-19-00
4
2017-03-10
Relapsed or Refractory Chronic Lymphocytic Leukemia
-
2024-511348-25-00
10
2015-12-11
Myelodysplastic syndromes (MDS)
-
2024-511096-15-00
5
2014-08-01
Breast Cancer
-
2024-511640-11-00
5
2014-05-15
Follicular lymphoma
-
2023-509197-35-00
5
2024-10-17
Thyroid Eye Disease (TED)
-
2023-506696-10-00
5
2024-06-18
Non-Small Cell Lung Cancer
-
2022-501781-22-00
5
2024-02-09
Generalised lipodystrophy
-
2023-503315-15-00
4
2023-12-20
Thrombolysis of symptomatic proximal vein thrombosis
-
2022-502196-31-00
10
2023-08-21
Advanced or Recurrent Endometrial Cancer
-
2022-502620-49-00
2
2023-08-01
Resected Melanoma Stage III or Stage IV
-
2024-518753-42-00
5
2023-03-30
Low back pain (LBP). LBP is one of the most frequent and disabling hea
-
2023-503794-38-00
5
2022-11-24
Prevention of stroke or systemic embolism in atrial fibrillation
-
2023-509569-19-00
10
2022-08-10
venous thromboembolism (VTE)
-
2024-513559-34-00
5
2022-07-19
Small Cell Lung Cancer (SCLC)
-
2024-515090-96-00
11
2022-05-10
Thyroid Eye Disease